Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:

• Camp4 Therapeutics (CAMP), 5,808% surge in interest

Pipeline and key clinical candidates for these companies:

Camp4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. The company’s approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, its therapeutic ASO drug candidates target regulatory RNAs, which act locally on transcription factors and are the master regulators of gene expression.

Recent news on these stocks:

September 10

Camp4 Therapeutics entered into definitive securities purchase agreements with certain institutional and accredited investors for up to $100M in gross proceeds through a private placement. Camp4 intends to use the net proceeds from the private placement to fund the preclinical and clinical development of its SYNGAP1 program, working capital, and general corporate purposes. The private placement is comprised of an initial upfront financing of $50M in gross proceeds in exchange for 26,681,053 shares of common stock priced at $1.53 per share of common stock sold at the initial closing, 36,361 shares of common stock priced at $1.65 to certain directors, employees and consultants of Camp4 at the initial closing, and 6,003,758 pre-funded warrants in lieu of common stock for $1.5299 for each pre-funded warrant sold in lieu of common stock at the initial closing. In addition, Camp4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for up to 32,721,172 shares of common stock, subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01. The financing is being led by new investor Coastlands Capital, and includes participation from additional new and existing investors including Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management, Trails Edge Capital Partners and the SynGAP Research Fund. Leerink Partners is acting as lead placement agent for the financing. Piper Sandler & Co., Cantor Fitzgerald, and Wedbush & Co. are acting as co-placement agents for the financing.

Concurrently with the financing, James Boylan, Ravi Thadhani, M.D., and Paula Ragan, Ph.D., have resigned from the Board of Directors. In conjunction, the Camp4 Board of Directors has appointed Doug Williams, Ph.D., as Board Chair, while Steven Holtzman has transitioned from Board Chair to Independent Director. Additionally, the company has elevated Daniel Tardiff, Ph.D., the company’s SVP, Head of Discovery, to its Chief Scientific Officer, effective October 1, 2025. David Bumcrot, Ph.D., will transition to the role of Scientific Fellow. Both will work closely with board member Murray Stewart, DM FRCP, who will become Chair of the Company’s Research and Development committee.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.